

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

Information for the public

Published: 3 May 2023

www.nice.org.uk

Tafasitamab (Minjuvi) with lenalidomide is not normally available on the NHS for treating relapsed or refractory diffuse large B-cell lymphoma. Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpage on non-Hodgkin lymphoma](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Lymphoma Action](#) 0808 808 5555
- [Cancer Research UK](#) 0808 800 4040
- [Macmillan Cancer Support](#) 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5150-5